Oncotelic Therapeutics ($OTLC) Valuation Is Massive is a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments for high-unmet-need cancers and rare pediatric conditions. The company’s pipeline is supported by CEO Dr. Vuong Trieu’s extensive IP portfolio, over 500 patent filings and 75 issued patents, and by strategic partnerships. Oncotelic also owns 45% of GMP Bio, a joint venture advancing complementary drug candidates that strengthen its position in oncology and rare diseases.
https://www.youtube.com/watch?v=tgs-nMq9J-E